Revealdx
RevealDx develops RevealAI-Lung, computer-aided diagnostic software that analyzes radiomic features in chest CT scans and gives radiologists a malignancy similarity score for individual lung nodules. It aims to help clinicians identify which nodules need earlier follow-up and guide patients onto the right care pathway sooner.
Facts
- HQ
- Seattle, WA
- Sectors
- Healthcare, Medical Software, AI/ML, Radiology
- Founded
- 2022 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- Precision Medical Ventures Inc Seattle business license
- Stage
- Seed
- Founders
- Michael Calhoun, PhD
Is this your organization? Claim it
Mazhar Mohammed leaves Microsoft after 33 years to join AWS as VP of Streaming and Messaging; Microsoft hires Chad Thompson from Alteryx as CVP of Agent Cloud
Several senior personnel moves in the Seattle tech and biotech scene: longtime Microsoft executive Mazhar Mohammed left for AWS, Microsoft hired Chad Thompson from Alteryx as CVP of Agent Cloud, Kimberly Ma joined Lila Bio as chief development officer, and BECU and Amazon named other finance and AI leaders.
4DMedical Invests $3.4M in RevealDx and Gains Rights to Distribute FDA-Cleared RevealAI-Lung Across US, Europe, Australia, New Zealand
RevealDx secured a $3.4 million strategic investment from 4DMedical and a distribution agreement to expand its FDA-cleared RevealAI-Lung nodule characterization software across the US, Europe, Australia, and New Zealand, integrating into clinical workflows and contextflow’s platform to help radiologists stratify lung cancer risk.
RevealDx secures $3.4M from 4D Medical and global distribution for RevealAI-Lung across US, Europe, Australia, New Zealand
RevealDx raised $3.4 million from 4D Medical and struck a distribution agreement to have 4D Medical sell its RevealAI-Lung diagnostic software across the US, Europe, Australia, and New Zealand; the tool scores incidental lung nodules on CT using a Malignancy Similarity Index to guide radiologist follow-up. The software is validated on over 1,500 patients, holds CE, TGA and FDA clearances, and is reimbursable by Medicare under CPT codes 0721T and 0722T.
See all 7 stories, episodes and videos about Revealdx.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
Chris Wood Executive, Chief Executive Officer